Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03070236 · ClinicalTrials.gov registry record · NA
PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions
A NA study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 912
- Enrollment target
- 6
- Study locations
NCT03070236: Active NA study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.
NCT03070236 is a NA study of Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 912 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (67% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03070236, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 912 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is evaluating how patients feel physically and emotionally after a prior breast biopsy for specific breast conditions (including atypical lesions such as atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and/or ductal carcinoma in situ (DCIS))
Primary Outcome
The Breast Cancer Pain Questionnaire (BCPQ) is a validated, self-reported instrument assessing pain severity, pain frequency (how many days per week), and pain location (breast, arm, side, axilla) over the last 2-week period with an average of 45.8 months from treatment for the two groups, Guideline Concordant Care (GCC) and Active Surveillance (AS). The Pain Burden Index (PBI) is a composite of pain severity, pain frequency, and pain location. Each severity answer is multiplied by each frequenc
Conditions Studied
Interventions
- OTHER Survey
Study Locations (6)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Newton-Wellesley Hospital - Newton
- Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital - Weymouth
North Carolina
- Duke University Medical Center - Durham
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 912 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2030-02-25 |
| Phase | NA |
What the registry record for NCT03070236 still lists
NCT03070236 is an interventional study that assigns participants to a tested intervention. The registered 912 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Survey is the first listed.
NCT03070236 lists 6 locations in 3 states (Massachusetts, North Carolina, Texas).
Frequently Asked Questions
What is clinical trial NCT03070236 about?
NCT03070236 is a clinical study titled "PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions". This research study is evaluating how patients feel physically and emotionally after a prior breast biopsy for specific breast conditions (including atypical lesions such as atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and/or ductal carcino...
What is the current status of trial NCT03070236?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 912 participants. The study started on 2017-12-01. Estimated completion is 2030-02-25.
What conditions does trial NCT03070236 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03070236?
The interventions under investigation include: Survey (OTHER).
Who is sponsoring clinical trial NCT03070236?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03070236 being conducted?
This trial has 6 study locations across Massachusetts, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03070236's enrollment target sits among peer trials
912 136th of 1224 higher than 1,089 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI